Utibron Neohaler

Active Ingredient(s): Indacaterol + Glycopyrrolate
FDA Approved: * October 29, 2015
Category: Lungs (Pulmonary)

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Utibron Neohaler Overview

Indacaterol is an ultra-long-acting beta-adrenoceptor agonist[5] developed by Novartis. It needs to be taken only once a day,[6] unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered as an aerosol formulation through a dry powder inhaler. Medical uses A Cochrane review found benefit in lung functi...

Read more Utibron Neohaler Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Indacaterol

Recent Utibron Neohaler Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Indacaterol + Glycopyrrolate
  • Powder: 15.6mcg/inh + 27.5mcg/inh, 27.5mcg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Utibron Neohaler: (2 results)

Sorted by National Drug Code
  • 0078-0664 Utibron Neohaler Respiratory (Inhalation) Capsule by Novartis Pharmaceuticals Corporation
  • 63402-681 Utibron Neohaler Respiratory (Inhalation) Capsule by Sunovion Pharmaceuticals Inc.

Drugs with one or more similar ingredients: (14 results)